(Communicated by Kiyoshi TAKEWAxl, M. J. A., Sept. 12, 1986) It has been reported that tumor frequency is lower in hyperthyroid and higher in hyperhyroid than in euthyroid humans.l>-4) In rodents, however, conflicting effects of different thyroid states on the development of tumors have been described : injections of thyroxine (T4) were reported to enhance rejection of transplanted Ehrlich ascites carcinoma cells in mice.J~ On the contrary, some workers reported stimulation by thyroxine of the development, growth and/or metastasis of rat mammary°) and mouse S-1 and T-241 tumors. 7) Hypothyroidism produced by antithyroid drugs was said to result in an increases) or decrease9)-11) in the incidence of carcinogen-induced rat mammary tumors. Spontaneous mammary tumors were less frequent in mice of a high mammary-tumor strain receiving an antithyroid-drug.12)
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Mono-and di-iodotyrosines (MIT and DIT) are generally accepted to be the precursors of thyroid hormones. It has also been suggested that iodotyrosines are formed by cleavage of the ether link of T4 and triiodothyronine (T3) in peripheral tissues.13>'1J> Basal blood concentrations of DIT are lower in hypothyroid and higher in hyperthyroid human individuals as compared to euthyroid sub jects.13)-15)
In the present study, we report that mammary and adrenocortical tumor grafts undergo regression in some of the host mice given intravenous infusions of MIT or DIT prior to transplantation.
Materials and methods. Normal male and female C3H/Tw mice aged 3-4 months were used for the experiments.
Male mice were castrated at the time of tumor transplantation (Tr). In this laboratory, a spontaneous mammary tumor (MT) derived from a female C3H/Tw mouse was successively transplanted under the abdominal skin of syngeneic normal females. An adrenocortical tumor (AT) found in a castrated aged male C3H/Tw mouse was also successively transplanted subcutaneously into syngeneic castrated males. Poorly differentiated adenocarcinomatous MT and AT obtained from the 41st-60th and the 178th-192nd transfer generations, respectively, were used in the experiments. Transplanted tumor piece was about 1.0 mm3 in initial volume, consisting of 0.98-1.00 X 106 cells. Volumes of tumor grafts were calculated as rotation ellipsoid (2rab2/6; a, b=long and short diameters).
On the 31st day after Tr, if tumor grafts in experimental mice were less than 10% of the mean tumor graft volume in the controls, the graft growth was judged as suppressed. Intravenous infusions were carried out 9 or 15 weeks before transplantation, except for 3 DIT-infused groups (see Table I ). The chemicals for infusion (vide infra, purchased from Sigma Chem. Co., St. Louis) were dissolved in a modified Tyrode solution without CaCl2, a precipitant of iodotyrosines, pH being adjusted to 12.3 with 0.2 M NaOH. Heparin sodium (15 units/ml) was added to the solution. The final pH of solutions varied with nature and concentration of solutes : 10.1 (15 mM MIT), 10.6 (15 mM DIT), 9.4 (30 mM DIT). Solutions of 15 or 30 mM of MIT, DIT, tyrosine and NaI were infused into the tail vein of mice. Since the solutions containing more than 0.3 mM T4 caused the infarction of blood vessels at the infusion site, the maximum dose of T4 used was 0.15 mM. The solutions were filtered through millipore filter (pore size, 0.22 µm) before infusion. Mice were given a 50-minute infusion followed by a 10-minute intermission per hour repetitively for 3 days by means of a microinfusion apparatus with programmed timer (Type D, Natsume Co., Tokyo, and Cosmotec Co., Yokohama).
The details of the intravenous (iv) infusion method were described previously.l6)
The infused volume of solution was 1.8 ml/day. Mice given a 3-day iv infusion of the modified Tyrode solution (pH 10.6) served as controls. Body weights of the mice were recorded immediately before and every 5 days after Tr. Net body weights of mice bearing tumors were calculated by BW--SGXTV (BW, weight of animal with tumor; SG, specific gravity of tumor (MT=1.054, AT=1.044; TV, tumor volume) ). 
Results.
Body weight (Fig. 2) . All groups of experimental and control mice showed a slight decrease in body weight (BW) after infusion which was restored soon later. In 2 groups of AT graft-bearing mice given infusions of 30 and 15 mM DIT 9 and 15 weeks (W) before Tr, respectively, mean net BWs were unchanged for 30 days after Tr, whereas in the remaining groups, mean BWs became decreased or fluctuated with growth of the grafts.
Regression o f tumor grafts (Table I , Fig. 1 ) . Examination for 30 days after Tr showed that in the control mice bearing tumors transplanted 9 or 15 W after iv infusion of the vehicle alone, both MT and AT grafts grew well, indicating no sign of regression.
Similarly, neither regression nor growth-suppression took place in the grafts in the animals given infusions of 15 mM tyrosine or NaI 9 W before as well as those receiving infusions of 15 or 30 mM DIT 3 W before.
By contrast, MT grafts disappeared in 10 and 38% of hosts given infusions of 30 and 15 mM DIT 9 W before (abridged as 9 W 30 and 15 mM DIT-hosts), respectively. In 15 W 15 mM DIT-hosts, none of the MT grafts regressed completely, only showing a growth suppression (14% ) . MT grafts disappeared in 22 and 9 % of 9 and 15 W 15 mM MIT-hosts, respectively. Growth was suppressed in MT graft in a 9 W 15 mM MIT-host (11%). In 30% of 9 W 0.15 mM T4-hosts, MT grafts disappeared, but in the rest of the hosts grafts were well developed.
AT grafts disappeared in 9°0 of 9 W 15 mM DIT-, 25% of 9 W 30 mM DIT-and 10% of 15 W 30 mM PIT-hosts.
In 21% of 15 W 15 mM DIT-hosts, AT grafts showed a transient regression followed by recurrence, complete regression never taking place. Growth suppression of AT grafts was observed in 42% of 9 W 30 mM DIT-, 36% of 15 W 15 mM DIT-, 14% of 15 W 30 mM DIT-, 20% of 9 W 15 mM MIT-and 40% of 15 W 15 mM MIT-hosts.
Suppression o f tumor grafts (Table I , Fig. 2 ) . The mean volume of MT grafts in the experimental groups was not significantly different from that in the control groups on the 31st day after Tr. In 9 W 30 mM DIT-, 15 W 15 mM DIT-, 15 W 30 mM DIT-and 15 W 15 mM MIT-hosts, however, AT grafts were significantly smaller in the mean volume than in the controls. In 9 W 15 mM DIT-, 9 W 15 mM MIT-hosts (MT), 9 W 30 mM DIT-, 15 W 15 mM DIT-and 15 W 15 mM MIT-hosts (AT), the total of incidences of complete and transient tumor regression and tumor growth suppression (A+B+C in Table I ) was significantly higher than in the matched controls.
Survival time (Table I ). The hosts of MIT-and DIT-infused groups in which MT or AT grafts had disappeared survived for more than 5 months after the tumors had become unpalpable.
In those infused with T4, 3 of 10 MT-hosts could survive for longer periods of time, but all of AT-hosts were shorter-lived. Some of the MT and AT-hosts having shown tumor growth suppression or transient tumor regression followed by recurrence survived for more than 3 months, but died within 4 months after Tr. The mean survival time of 9 W 15 mM DIT-hosts (MT), 15 W 15 mM DIT-, 15 W 30 mM DIT-and 15 W 15 mM MIT-hosts (AT) which had died within 3 months after Tr was significantly longer than that of the controls.
In 9 W 15 mM DIT-, 9 W 15 mM MIT-hosts (MT) and 9 W 30 mM DIT-hosts (AT), significantly greater number of hosts survived for more than 3 months as compared to the controls.
Discussion.
The present results demonstrated that in mice given 3-day iv infusions of large doses of MIT or DIT, some of MT-and AT-grafts transplanted 9 or 15 weeks after infusion disappeared, whereas those transplanted 3 weeks post-infusion remained unaffected. MT grafts also disappeared in some T4-infused hosts, although the T4 infusion had no suppressive effects on AT grafts. The incidence of complete MT regression and the total of incidences of complete and transient regression and growth suppression of MT (A+B+C in Table I ) in T4-hosts were not always higher than those in MIT-and DIT-hosts.
Since the half-life of MIT and DIT in the blood and tissues is much shorter as compared with that of T4,17),18) it is likely that in T4-hosts a high blood levels of T4 is sustained for a longer period than the levels of the iodotyrosines in MIT-and DIT-hosts. On the basis of previous studies suggesting the production of iodotyrosines from T3 and T4,'3>,1~) it is conjectured that elevated blood levels of iodotyrosines are maintained for a longer period of time in T4-hosts. The findings that iv infusions of NaI and tyrosine have no suppressive effect on MT and AT grafts appear to show that iodine and tyrosine presumably derived from iodotyrosines exert no inhibitory effect on the tumors.
In conclusion, infusions of iodotyrosines may have an inhibitory effect on later transplanted mammary and adrenocortical tumors.
